News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Johnson & Johnson (JNJ) Anti-Depressant Related to "Special K" Party Drug



5/24/2013 8:16:51 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Johnson & Johnson said it plans to seek approvals for 11 new drugs by 2017, including a treatment for patients with depression who have failed to benefit from standard medications. The intranasal drug, called esketamine, is closely related to a pediatric anesthetic called ketamine that has been shown in academic studies to ease symptoms rapidly in such patients, including a reduction in suicidal thoughts. Ketamine is also the active ingredient of the mood-altering party drug known as "Special K." J&J, which is testing its tweaked version of ketamine in mid-stage trials, on Thursday said initial findings have been promising.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Forbes
Read at Fox News
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES